Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite surges for obesity drugmakers Eli Lilly and Novo Nordisk. But the sector is off to a healthy start in 2025.

However, its low valuation could have investors wondering if now is the right time to take a chance on the business, especially before it releases its year-end earnings numbers on Feb. 12. Let's take a look at whether CVS could potentially be an underrated buy right now.

Shares of CVS Group traded about 1% lower on Thursday following the company's first-half earnings report which revealed a slight revenue shortfall against consensus expectations, but in-line EBITDA figures.